)
)
)
Dawn Bardot, PhD
CEO & Co-Founder,
Zula Therapeutics
Dawn Bardot, PhD, is CEO and co-founder of Zula Therapeutics, developing the first medicine for anorexia nervosa, the deadliest psychiatric disease. She was most recently General Manager at Abiomed, a Johnson & Johnson company, where she led a $60M global business and scaled an FDA-approved connected platform to more than 2,600 hospitals across the US, Europe and Japan. Earlier she held leadership roles at Medtronic and at the Medical Device Innovation Consortium (MDIC), where she led the proposal and stand-up of NESTcc, the FDA-funded real-world evidence coordinating center. She holds a PhD from the University of Washington.